MRD Testing Strengthens Oncology Care

How to Predict Better Treatment Outcomes through Best Practices in Genomics and Flow Cytometry for MRD Testing

white paper download button

As one of the most reliable predictors of treatment outcomes for multiple forms of cancer, Measurement of Residual Disease (MRD) testing presents many new opportunities for improvement in clinical trials.

In this complimentary white paper, discover best practices revealed by our top oncology experts in MRD testing that you should be using now in your drug development program. Our experts will also discuss the advantages and disadvantages of two leading approaches in MRD testing – Genomics and Flow Cytometry – and how to choose the most optimal one for your particular study.

Contact us today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.

About the authors:
Mark Edinger, Director, Scientific Advisor, Flow Cytometry
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics
Franklin Sedarat, M.D., M.Sc., FCAP, Director of Hematopathology
Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Q2 Solutions Central Laboratory Services

Optimized logistics, deeper science, better insights

Q2 Solutions central laboratory services in China

Local Chinese market knowledge with global experience to support your local, regional or global development program

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Read More